Research and Markets has announced the addition of the "Fibrosarcoma - Pipeline Review, H2 2016" report to their offering.
Fibrosarcoma pipeline therapeutics constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by Companies and remaining by the Universities
Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Fibrosarcoma Fibrosarcoma is a malignant tumor derived from fibrous connective tissue. Symptoms include local pain, local swelling, local warmth, dilated blood vessels pain and swelling of the bone, pathological fractures, neurological and vascular changes.
Fibrosarcoma - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Fibrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Fibrosarcoma and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/rlg6kt/fibrosarcoma
Related Topics: Oncology Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005844/en/Business Wire
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.